1. Savara Inc. announces participation in two healthcare conferences. 2. Management will present and hold 1x1 meetings at these events. 3. MOLBREEVI is under Phase 3 development for autoimmune pulmonary diseases. 4. Conferences are on September 3 and 9, 2025. 5. Live webcasts will be accessible on the company's website.
Participation in major healthcare conferences typically boosts visibility and investor interest. Historical examples show enhanced stock performance post-conference announcements for biopharma firms.
The article highlights upcoming events that may attract investor attention, potentially raising SVRA's profile. Given Savara's focus on innovative therapies, this is a significant positive signal.
The upcoming conferences and investor meetings can lead to immediate market reactions. Positive engagements often prompt short-term investment spikes.
Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at two upcoming healthcare conferences.
Wells Fargo Securities Healthcare Conference
September 3, 2025, 4:30pm ET/1:30pm PT
H.C. Wainwright Global Healthcare Conference
September 9, 2025, 1:00pm ET/10:00am PT
The live webcasts and subsequent replays will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 90 days.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com and LinkedIn.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250826241881/en/
Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
ir@savarapharma.com